Phase 2 clinical trial of a novel t cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant
Active Project Grant Awarded Last action
- Award ID
- R44CA285177
- Recipient
-
Marker Therapeutics Inc. UEI CK3KR85CSP23
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,659,352
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 81% complete
- Originally
- Place of performance
- Houston, TX 77021, USA
Award details come from USAspending.gov.
Description
- Abstract
- This phase II application will advance MT-401, a novel multi-tumor associated antigen (mtaa)-specific t cell product for the treatment of acute myeloid leukemia (AML) and other cancers. In the USA, ~3,500 AML patients receive hematopoietic stem cell therapy (hsct) every year, but overall survival remains
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $664,838 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $664,838 | |
| Amendment | $664,838 | |
| Original award | $664,838 |
Quick answers
Who received award R44CA285177?
R44CA285177 was awarded to Marker Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on August 10, 2023.
How much is award R44CA285177 worth?
$2,659,352 has been obligated on R44CA285177.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award